Effects of Xuezhikang and Pravastatin on circulating endothelial progenitor cells in patients with essential hypertension

Chinese Journal of Integrative Medicine

Volumn 15, Issue 4, 2009, Pages 266-271

  Lu, Li ^a   Zhou, Jian Zhong ^a   Wang, Li ^b   Zhang, Tie Xu ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b First People's Hospital of Jiulongpo District   (China)

Author keywords

Endothelial progenitor cell; Essential hypertension; Pravastatin; Xuezhikang

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; PRAVASTATIN; XUEZHIKANG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CELL ADHESION; CELL COUNT; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN CELL; LASER MICROSCOPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEM CELL;

AGED; ANTICHOLESTEREMIC AGENTS; ANTIDIURETIC AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD CELL COUNT; CALCIUM CHANNEL BLOCKERS; CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYPERTENSION; INTEGRATIVE MEDICINE; MALE; MIDDLE AGED; PRAVASTATIN; STEM CELLS;

EID: 70350103233     PISSN: 16720415     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11655-009-0266-x     Document Type: Article

References (15)

1. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999-1007.
2. Schmidt-Lucke C, Rössig L, Fichtischerer S, Vasa M, Britten M, Kämper U, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111:2981-2987.
3. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, et al. HMG-CoA reductase inhibitors (statins) Increase endothelial progenitor cells via the PI 3-kinase Akt pathway. J Clin Invest 2001;108:391-397.
4. Assmus B, Urbich C, Aicher A, Hofmann WK, Haendeler J, Rössig L, et al. HMG-CoA reducase inhibitors reduce senescence and increase proliferation of endothelial progenitors via regulation of cell cycle regulatory gene. Circ Res 2003;92:1049-1055.
5. Guideline Subcommittee. 1999 World Health Organization-international Society of Hypertension. Guidlines for the management of hypertension of Hypertension. J Hypertens 1999;17:151-183.
6. Yao EH, Fukuda N, Matsumoto T, Kobayashi N, Katakawa M, Yamamoto C, et al. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res 2007;30:1119-1128.
7. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-967.
8. Gulati R, Jevremovic D, Peterson TE, Witt TA, Kleppe LS, Mueske CS, et al. Autologous culture-modified mononuclear cells confer vascular protection after arterial injury. Circulation 2003;108:1520-1526.
9. Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens 2005;23:1831-1837.
10. Lu L, Zhou JZ, Zhang TX, Wang Z, Hang LW. Influence of essential hypertension on circulating endothelial progenitor cells. Chin Gener Pract (Chin) 2008;11: 744-746.
11. Rupp S, Badorff C, Koyanagi M, Urbich C, Fichtischerer S, Aicher A, et al. Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells. Basic Res Cardiol 2004;99:61-68.
12. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel I). Third report of the national cholesterol education program (NECP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults final report. Circulation 2002;1063:3143-3146.
13. Matsubara K, Yamamoto Y, Sonoyama K, Igawa G, Furuse M, Yatsuhashi T, et al. Current status of lipid management of hypertensive patients. Hypertens Res 2003;26:699-704.
14. Vasa M, Fichtischerer S, Adler K, Aicher A, Martin H, Zeiher AM, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-2890.
15. Zhao SP, Liu L, Cheng YC, Shishehbor MH, Liu MH, Peng DQ, et al. Xuezhikang, an extract of Cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004;110:915-920.